Halozyme Therapeutics (HALO) Receivables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Receivables data on file, last reported at $458.0 million in Q1 2026.

• Receivables for Q1 2026 came in at $458.0 million, up 50.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $458.0 million (up 50.35% YoY), and the FY2025 annual result was $441.3 million, up 34.23% from the prior year.
• Receivables climbed to $458.0 million in Q1 2026 per HALO's latest filing, from $441.3 million in the prior quarter.
• Over five years, Receivables peaked at $458.0 million in Q1 2026 and troughed at $115.0 million in Q1 2022.
• A 5-year average of $273.7 million and a median of $235.2 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables jumped 169.82% in 2022, then slipped 27.06% in 2023.
• A 5-year view of Receivables shows it stood at $231.1 million in 2022, then advanced by 1.79% to $235.2 million in 2023, then jumped by 39.77% to $328.8 million in 2024, then soared by 34.23% to $441.3 million in 2025, then rose by 3.79% to $458.0 million in 2026.
• Business Quant data shows HALO's Receivables at $458.0 million in Q1 2026, $441.3 million in Q4 2025, and $346.0 million in Q3 2025.